Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease
Posted by amanda punzalan under Press (No Respond)
Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease SOUTH SAN FRANCISCO, CA., Aug. 31, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the…